Sequenom: Breadth of '540 Patent Creates Vulnerability to Validity Challenge Despite Strength of Claims – Attorneys
 

Brenda Jarrell Quoted on Sequenom and the '540 Patent in BioPharm Insight

BioPharm Insight

 | February 24, 2012

 | Brenda Jarrell

Brenda Jarrell, PhD, was quoted in “Sequenom: Breadth of '540 Patent Creates Vulnerability to Validity Challenge Despite Strength of Claims – Attorneys” in BioPharm Insight, an industry news and data resource for subscribers in the global biopharmaceutical community.  Ms. Jarrell discusses likely arguments in the current litigation between prenatal diagnostics developers Sequenom and Aria Diagnostics regarding tests for the non-invasive diagnosis of Down Syndrome. 

 

Thank you for reaching out to contact Choate. Before you send your message, we wanted to make sure you are aware of the following. Please do not send any confidential information in response to this link. Sending an e-mail to Choate does not give rise to an attorney-client relationship, and will not be deemed to disqualify Choate from undertaking any engagement for a current or future client.  Before any attorney-client engagement may be formed, Choate will need to check for possible conflicts of interest, you will need to consider whether you wish to retain Choate as counsel, and we will need to consider whether we wish to accept the potential engagement. In the meantime, Choate reserves the right to represent parties with interests adverse to you.

AcceptDecline